GENE ONLINE|News &
Opinion
Blog

2018-11-14| Trials & Approvals

New hepatocellular carcinoma approval for Pembrolizumab – KN-224

by GeneOnline
Share To

By Ajay V. Patil

The US FDA granted pembrolizumab (Keytruda) an accelerated approval for the treatment of patients with hepatocellular carcinoma (HCC) who have previously received sorafenib (November 9, 2018 press release Merck & Co.). The accelerated approval of pembrolizumab in HCC is contingent on the results of a confirmatory trial.

The base study which supported this decision, phase II KEYNOTE-224 trial, showed that pembrolizumab singularly induced an overall response rate (ORR) of 17% (95% CI, 11-26) among 104 patients with advanced HCC previously treated with sorafenib. Among the 18 responding patients, there was 1 complete response and 17 partial responses. Among the responding patients (n=18), 89 percent experienced a duration of response (DOR) for six months or longer and 56 percent experienced a DOR for 12 months or longer. The median PFS was 4.9 months (95% CI, 3.4-7.2), and the 12-month PFS rate was 28% (95% CI, 19-37). The median OS was 12.9 months (95% CI, 9.7-15.5) and the 12-month OS rate was 54% (95% CI, 44-63). Patients received pembrolizumab for a median of 4.2 months (range, 2.1-7.7). Progressive disease (57%) and adverse events (AEs; 23%) were most frequent causes of the treatment discontinuation.

KEYNOTE-224 Study Design

Nonrandomized, open-label phase II trial enrolled and treated 104 patients with HCC and prior sorafenib (between June 7, 2016 and February 9, 2017) at 47 medical centers and hospitals in 10 countries. Eighty percent of patients had discontinued sorafenib due to progressive disease and 20% had become intolerant to sorafenib. There were 86 males and 18 females in the trial, and the median age was 68 (range, 62-73). Ninety-four percent of patients were Child Pugh Class A and 76% had Barcelona Clinic Liver Cancer stage C disease. Eighty-one percent of patients were white, 13% were Asian, and 3% were black. All patients had an ECOG performance score of 0 (61%) or 1 (39%).

Patients were treated with 200 mg of intravenous pembrolizumab administered every 3 weeks on day 1 of each 3-week cycle. Treatment continued until progression, unacceptable toxicity, withdrawal of patient consent, investigator decision, or a maximum of 35 cycles (approximately 2 years). The primary endpoint was ORR, and secondary endpoints included duration of response (DOR), disease control, time to progression, progression-free survival (PFS), overall survival (OS), and safety. Seventeen (16%) patients still receiving pembrolizumab (at the February 13, 2018, data cutoff).

This is another major milestone for pembrolizumab in HCC space, post its announcement of data at 2018 ASCO annual meeting from investigational studies of lenvatinib and pembrolizumab combination therapy in four different tumor types including HCC.

References

  1. https://investors.merck.com/news/press-release-details/2018/FDA-Approves-Mercks-KEYTRUDA-pembrolizumab-for-the-Treatment-of-Patients-with-Hepatocellular-Carcinoma-HCC-Who-Have-Been-Previously-Treated-with-Sorafenib/default.aspx
  2. https://www.onclive.com/web-exclusives/fda-approves-pembrolizumab-for-hcc
  3. https://www.eisai.com/news/2018/news201843.html

 

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
Fake Ozempic Floods Market as FDA Warns Patients to Check Authenticity of Prescriptions
2025-04-16
Breaking New Ground in 2025 with 8 First-in-Class Drugs Close to FDA Approval – Part II
2025-04-01
Breaking New Ground in 2025 with 8 First-in-Class Drugs Close to FDA Approval – Part I
2025-03-31
LATEST
AI-Based Model Accurately Classifies Pediatric Sarcomas Using Digital Pathology Images
2025-04-30
Taiwan’s BPIPO and DCB Join Japan’s LINK-J and FIRM for First Regenerative Medicine Investment Forum in Tokyo
2025-04-29
Study Shows ctDNA Liquid Biopsy Detects Colorectal Cancer Recurrence Earlier Than Imaging
2025-04-29
AACR Annual Meeting 2025: Cancer Research Innovations, NIH Funding Advocacy, and AI-Driven Advances
2025-04-28
Senti Biosciences to Showcase New Cell & Gene Therapy Data at AACR Annual Meeting 2025
2025-04-27
World Vaccine Congress Washington 2025 Recap: Urgent Calls for Trust, Tech, and Global Access
2025-04-25
Astellas’ Transformation Journey: From Merger to Global Player, Betting on the Edge of Innovation and Risk?
2025-04-25
EVENT
2025-04-25
AACR Annual Meeting 2025
Chicago, U.S.A
2025-05-03
29th Taiwan Joint Cancer Conference 2025
Taipei, Taiwan
2025-05-05
Swiss Biotech Day 2025
Basel, Switzerland
2025-05-13
ASGCT 28th Annual Meeting 2025
New Orleans, U.S.A.
2025-05-30
ASCO Annual Meeting 2025
Chicago, U.S.A
2025-06-11
ISSCR 2025 Annual Meeting
Hong Kong
Scroll to Top